CD274 and pancreatic neoplasm: Ruxolitinib combined with PD-L1 inhibitor (RMP1-14) can up-regulate the infiltration and activation of cytotoxic T lymphocyte, so as to overcome the resistance of pancreatic cancer to anti-PD-1 immunotherapy [114].